Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Clearmind says the Japanese publication strengthens its global intellectual property position for its 3-MMC-based dyskinesia approach.

Rhea-AI Summary

Clearmind Medicine (CMND) announced publication in Japan of a patent application covering its 3-MMC-based approach to treating dyskinesia, a neurological movement disorder.

The application covers preventing, treating or reducing dyskinesia symptoms, including pharmaceutical compositions containing 3-MMC. It also includes claims for combinations with N-acylethanolamines, notably Palmitoylethanolamide (PEA). Dyskinesia is characterized by involuntary movements. The applications form part of Clearmind’s ongoing collaboration with NeuroThera Labs, which integrates PEA technology into Clearmind’s psychedelic-derived therapeutic programs.

Positive

• Minor pointJapanese patent application publication advances Clearmind’s intellectual property strategy for its 3-MMC-based dyskinesia approach.

Negative

• None.

Historical Context

1 past event · Latest: Sep 23

1 event

1. Sep 23

   Patent applications

   24h Move

   +8.4%

   Clearmind published U.S. applications for LSD, ketamine and ibogaine combinations with PEA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dyskinesia, 3-methylmethcathinone, n-acylethanolamines, palmitoylethanolamide

4 terms

dyskinesia medical

"treating dyskinesia, a neurological movement disorder characterized by involuntary movements"

Dyskinesia is a medical condition marked by uncontrolled, often jerky or writhing movements of the body that a person cannot willfully stop, commonly arising as a side effect of neurological treatments or diseases. For investors, dyskinesia matters because its frequency, severity and manageability affect drug approval, labeling, patient adoption and long-term sales; think of it like a software bug that can undermine user trust and reduce market value if not fixed.

3-methylmethcathinone medical

"The published patent application covers the use of 3-Methylmethcathinone"

3‑methylmethcathinone is a synthetic stimulant drug in the cathinone chemical family, chemically related to cathinone and amphetamines. It acts on the brain by increasing levels of monoamine neurotransmitters (particularly dopamine, norepinephrine and serotonin), producing stimulant and entactogenic effects; it is commonly encountered in forensic, toxicology and regulatory contexts and is typically subject to controlled‑substance laws, though legal status varies by jurisdiction.

n-acylethanolamines medical

"combinations of 3-MMC with N-acylethanolamines"

N-acylethanolamines are a family of naturally occurring fatty molecules that act as small chemical messengers inside the body, helping cells communicate about inflammation, appetite, pain and other processes. Investors care because these molecules can be targets or biomarkers for drugs, diagnostics and wellness products — like a visible readout on a dashboard that indicates whether a treatment is working or a condition is present — which affects clinical development, regulatory approval and market potential.

palmitoylethanolamide medical

"notably Palmitoylethanolamide (“PEA”"

Palmitoylethanolamide (PEA) is a naturally occurring fatty molecule produced in the body and sold as a supplement or experimental therapy for reducing pain and inflammation; think of it as a built‑in calming signal that helps quiet irritated tissues. Investors watch PEA because its potential medical benefits, regulatory path (supplement vs. drug), and clinical evidence drive market demand, pricing and the risk/reward of companies developing or selling PEA-based products — similar to how a promising ingredient can change the fortunes of a consumer brand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions comprising 3-MMC. The application also includes claims for combinations of 3-MMC with N-acylethanolamines, notably Palmitoylethanolamide (“PEA”, a compound with established anti‑inflammatory and neuroprotective properties.

These patent applications are part of the ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage biotech company. Through this partnership with NeuroThera, PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs. “

Our strategy is to build robust intellectual property protection around our novel therapeutic platforms and their broad potential across neurological disorders,” said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind. “The publication of the patent application in Japan and strengthens our global IP position for our 3-MMC-based approach to dyskinesia, including its combination with PEA.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy is to build robust intellectual property protection around its novel therapeutic platforms and their broad potential across neurological disorders and strengthening our global IP position. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Clearmind’s Japanese dyskinesia patent application cover?

The published application covers 3-MMC for preventing, treating or reducing dyskinesia symptoms. Its claims include pharmaceutical compositions containing 3-MMC and combinations with N-acylethanolamines, notably PEA. The announced milestone is publication of a patent application, rather than a patent grant.